OncoMatch/Clinical Trials/NCT06751134
Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma
Is NCT06751134 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Chimeric Natural Killer Receptor Universal T-cells (CNK-UT) for neuroblastoma, recurrent, refractory.
Treatment: Chimeric Natural Killer Receptor Universal T-cells (CNK-UT) — This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, preliminary efficacy, pharmacokinetics of universal T-cells engineered with chimeric natural killer receptor (CNK-UT) to treat the patients with relapsed/refractory Neuroblastoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Neuroblastoma
Biomarker criteria
Required: CD276 expression (positive by ihc)
Demographics
Prior therapy
Must have received: induction chemotherapy — first-line
standard treatment protocols, which include induction chemotherapy, surgery, and radiotherapy targeting the primary tumor and residual metastatic sites
Must have received: surgery — first-line
standard treatment protocols, which include induction chemotherapy, surgery, and radiotherapy targeting the primary tumor and residual metastatic sites
Must have received: radiation therapy — first-line
standard treatment protocols, which include induction chemotherapy, surgery, and radiotherapy targeting the primary tumor and residual metastatic sites
Cannot have received: gene therapy
Participants who have used any gene therapy products prior to cell infusion
Lab requirements
Blood counts
ANC≥1.5×10^9/L; ALC≥0.2×10^9/L; Platelet count ≥75×10^9/L; Haemoglobin≥90g/L
Kidney function
Serum creatinine≤2×ULN, or Creatinine clearance rate (CCR)≥60 mL/min (Cockroft-Gault formula)
Liver function
Total bilirubin≤3×ULN; AST or ALT≤5×ULN
Cardiac function
LVEF≥50%; Cardiac function Grade I-II
Adequate organ and bone marrow function, and the laboratory test value meets the following requirements within 7 days before enrollment, as follows: (1)Blood Routine Test: Absolute neutrophil count(ANC)≥1.5×10^9/L;Absolute lymphocyte count (ALC)≥0.2×10^9/L；Platelet count ≥75×10^9/L; Haemoglobin≥90g/L; (2)Heart: Left ventricular ejection fraction (LVEF)≥50%;Cardiac function Grade I-II; (3)Pulmonary function: indoor oxygen saturation≥92%. (4)Hepatic function：Total bilirubin≤3×ULN; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)≤5×ULN; (5)Renal function: Serum creatinine≤2×ULN, or Creatinine clearance rate (CCR)≥60 mL/min (Cockroft-Gault formula);
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06751134 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene therapy disqualifies patients from enrollment.
Does this trial require CD276?
Yes, CD276 expression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 12 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages